Although the mechanisms involved in the development of hypertension are still not fully understood, the widespread use of medications that inhibit the formation of the peptide hormone angiotensin (Ang) II or its actions at the ubiquitously expressed Ang II type 1 (AT1) receptor as first‐line treatments implicates disturbances in the renin‐angiotensin system (RAS) in the maintenance of the disease (Herichova and Szantoova 2013). Here, AGTR1 is linked to hypertensive disorder.